

Facile synthesis of indolizinoindolone, indolylepoxypyrrolooxazole, indolylpyrrolooxazolone and isoindolopyrazinoindolone heterocycles from indole and imide derivatives[†]

Santosh V. Shelar^{a,b} and Narshinha P. Argade^{*a,b}

^aDivision of Organic Chemistry, National Chemical Laboratory (CSIR), Pune 411 008, India

np.argade@ncl.res.in

^bAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India


Supporting Information


Table of Contents


Page. No.	Contents
5	¹ H NMR spectrum of compound 2
6	¹³ C NMR spectrum of compound 2
7	DEPT spectrum of compound 2
8	¹ H NMR spectrum of compound 2a
9	¹³ C NMR spectrum of compound 2a
10	DEPT spectrum of compound 2a
11	¹ H NMR spectrum of compound 26
12	¹³ C NMR spectrum of compound 26
13	DEPT spectrum of compound 26
14	¹ H NMR spectrum of compound 4
15	¹³ C NMR spectrum of compound 4
16	¹ H NMR spectrum of compound 5
17	¹³ C NMR spectrum of compound 5
18	¹ H NMR spectrum of compound 6
19	¹³ C NMR spectrum of compound 6
20	¹ H NMR spectrum of compound 7
21	¹³ C NMR spectrum of compound 7
22	DEPT spectrum of compound 7
23	¹ H NMR spectrum of compound (±)- 9
24	¹³ C NMR spectrum of compound (±)- 9
25	¹ H NMR spectrum of compound 12
26	¹³ C NMR spectrum of compound 12
27	¹ H NMR spectrum of compound 13
28	¹³ C NMR spectrum of compound 13
29	DEPT spectrum of compound 13
30	¹ H NMR spectrum of compound 29


31	^{13}C NMR spectrum of compound 29
32	DEPT spectrum of compound 29
33	^1H NMR spectrum of compound ($\pm$)-15
34	^{13}C NMR spectrum of compound ($\pm$)-15
35	DEPT spectrum of compound ($\pm$)-15
36	^1H NMR spectrum of compound ($\pm$)-17
37	^{13}C NMR spectrum of compound ($\pm$)-17
38	^1H NMR spectrum of compound 19
39	^{13}C NMR spectrum of compound 19
40	DEPT spectrum of compound 19
41	^1H NMR spectrum of compound 32
42	^{13}C NMR spectrum of compound 32
43	DEPT spectrum of compound 32
44	^1H NMR spectrum of compound 21
45	^{13}C NMR spectrum of compound 21
46	DEPT spectrum of compound 21
47	^1H NMR spectrum of compound ($\pm$)-23
48	^{13}C NMR spectrum of compound ($\pm$)-23
49	DEPT spectrum of compound ($\pm$)-23
50	^1H NMR spectrum of compound ($\pm$)-28
51	^{13}C NMR spectrum of compound ($\pm$)-28
52	DEPT spectrum of compound ($\pm$)-28
53	^1H NMR spectrum of compound 31
54	^{13}C NMR spectrum of compound 31
55	DEPT spectrum of compound 31
56	^1H NMR spectrum of compound 34
57	^{13}C NMR spectrum of compound 34
58	DEPT spectrum of compound 34
59	^1H NMR spectrum of compound 35


60	¹³ C NMR spectrum of compound 35
61	¹ H NMR spectrum of compound 36
62	¹³ C NMR spectrum of compound 36
63	¹ H NMR spectrum of compound 38
64	¹³ C NMR spectrum of compound 38
65	¹ H NMR spectrum of compound 10a
66	¹³ C NMR spectrum of compound 10a
67	Table 1: Comparison ¹ H and ¹³ C NMR spectra for proposed natural product 10 and revised natural product (+)- 10a
69	X-ray crystallography data and crystal structure of compound (±)- 9
72	X-ray crystallography data and crystal structure of compound 38
75	References


























































(±)-9, ¹³C NMR, DMSO-*d*₆, 100 MHz
















13, DEPT, CDCl₃, 100 MHz
























(±)-17, ^{13}C NMR, $\text{DMSO-}d_6$, 100 MHz











19, DEPT, CDCl₃, 100 MHz














21, ¹³C NMR, CDCl₃, 100 MHz





C₁₈H₁₆N₂O₂
292.1212


21, DEPT, CDCl₃, 100 MHz





C₁₈H₁₆N₂O₂
292.1212















28, ^{13}C NMR, acetone- d_6 , 125 MHz




28, DEPT, acetone-*d*₆, 125 MHz











31, DEPT, CDCl₃, 100 MHz




















36, ^{13}C NMR, CDCl_3 , 100 MHz




38, ^1H NMR, DMSO- d_6 , 400 MHz




38, ^{13}C NMR, $\text{DMSO-}d_6$, 100 MHz



10a, ^1H NMR, DMSO- d_6 , 200 MHz



10a, ^{13}C NMR, DMSO- d_6 , 50 MHz



■ Table 1: Comparison ^1H and ^{13}C NMR spectral data of proposed natural product 10 and revised natural product (+)-10a

Proposed natural product 10 (reference 40 in manuscript)			Revised natural product 10a (present work)	
^1H NMR (DMSO- d_6 , 400 MHz) δ	^{13}C NMR (DMSO- d_6 , 100 MHz) δ (δ 40.0 ref. lock) [†]	^{13}C NMR (DMSO- d_6 , 100 MHz) δ (δ 39.5 ref. lock)	^1H NMR (DMSO- d_6 , 200 MHz) δ	^{13}C NMR (DMSO- d_6 , 50 MHz) δ (δ 39.5 ref. lock)
1.77 (m, 1H)	21.2	20.7	1.70–1.91 (m, 1H)	20.7
2.25 (m, 1H)	25.9	25.4	2.20–2.37 (m, 1H)	25.4
2.49 (m, 1H)	31.5	31.0		31.0
2.54 (m, 1H)	37.3	36.8	2.38–2.84 (m, 4H)	36.9
2.63 (m, 1H)	54.1	53.6		53.6
2.73 (dd, J = 15.2, 4.0 Hz, 1H)	106.4	105.9		105.9
2.95 (ddd, J = 12.4, 12.4, 4.0 Hz, 1H)	111.6	111.1	2.98 (dt, J = 12.1 and 4.9 Hz, 1H)	111.1
4.26 (dd, J = 12.4, 6.0 Hz, 1H)	118.3	117.8	4.27 (dd, J = 12.9 and 4.7 Hz, 1H)	117.8
4.89 (m, 1H)	119.1	118.6	4.91 (t, J = 7.3 Hz, 1H)	118.6
6.95 (br dd, J = 7.6, 7.2 Hz, 1H)	121.5	121.0	6.97 (dt, J = 7.1 and 0.9 Hz, 1H)	121.0
7.04 (br dd, J = 8.0, 7.2 Hz, 1H)	126.9	126.4	7.07 (dt, J = 6.9 and 1.3 Hz, 1H)	126.4
7.30 (br d, J = 8.0 Hz, 1H)	135.1	134.6	7.33 (d, J = 7.4 Hz, 1H)	134.6
7.38 (br d, J = 7.6 Hz, 1H)	136.6	136.1	7.40 (d, J = 7.3 Hz, 1H)	136.1
11.00 (br s, 1H)	172.8	172.3	11.04 (br s, 1H)	172.3

[†] In the isolation paper authors have locked the DMSO- d_6 signal at δ 40.00 (ref. 40)

■ General X-ray Crystallography Analysis

Single crystal data of all crystals were collected on Bruker SMART APEX II single crystal X-ray CCD diffractometer having graphite-monochromatized ($\text{Mo-K}\alpha = 0.71073 \text{ \AA}$) radiation at 100 K. The X-ray data acquisition was monitored by APEX2 program suit. The data were corrected for Lorentz-polarization and absorption effects using SAINT and SADABS programs which are integral part of APEX2 package. The structures were solved by direct methods and refined by full matrix least squares, based on F^2 , using SHELXL. Crystal structures were refined using Olex software. PLATON was used to check any higher symmetry of crystal, and mercury software was utilized for molecular representations and packing diagrams. Refinement of coordinates and anisotropic thermal parameters of non-hydrogen atoms were performed with the full-matrix least-squares method. Most of hydrogen atoms in NH/OH groups were located from the difference in Fourier maps. The hydrogen atoms of CH were calculated using the riding model¹⁻⁴.

■ X-ray crystallography data and crystal structure of compound ($\pm$)-**9**

The compound ($\pm$)-**9** (5 mg) was dissolved in methanol (2 mL), and two drops of chloroform added to obtain a clear solution and allowed to evaporate at room temperature in a vial. After 24h, colourless crystals were formed. Crystal analysis studies were done by Bruker APEX-II CCD (Figure 1 *vide infra*).

Crystal Structure was deposited at the Cambridge Crystallographic Data Centre. The data have been assigned the following deposition number.

Compound Code: ($\pm$)-**9** [CCDC number **2070970**]

■ Table 2. Crystal data and structure refinement for compound (±)-9

Compound 9	X-ray crystallography data
Empirical Formula	C ₁₄ H ₁₄ N ₂ O ₂
Formula weight	242.27
Crystal System	Orthorhombic
Space Group	<i>Pca</i> 2 ₁
T (K)	100
<i>a</i> (Å)	24.406 (2)
<i>b</i> (Å)	5.0265 (4)
<i>c</i> (Å)	9.4136 (8)
α (°)	90
β (°)	90
γ (°)	90
<i>V</i> (Å ³)	1154.83 (17)
<i>D</i> _{cal} (g cm ⁻³)	1.393 Mg m ⁻³
<i>Z</i>	4
μ (mm ⁻¹)	0.10
<i>R</i> _{int}	0.060
<i>R</i> [<i>F</i> ² > 2σ(<i>F</i> ²)]	0.036
<i>wR</i> (<i>F</i> ²)	0.106
(<i>sin</i> θ/λ) <i>max</i> (Å ⁻¹)	0.647
Crystal size (mm)	0.18 × 0.12 × 0.06
Measured reflections	38269
Independent reflections	2610
Reflections with <i>I</i> > 2σ(<i>I</i>)	2525
Goodness of fit (S)	1.19
X-ray Diffractometer	Bruker APEX-II CCD




Figure S1: Molecular structure (ORTEP diagram) of compound (±)-9 Ellipsoids are shown at 50% probability

■ X-ray crystallography data and crystal structure of compound **38**

The compound **38** (3 mg) was dissolved in ethyl acetate (2 mL) and two drops of acetonitrile added to obtain a clear solution and allowed to evaporate at room temperature in a vial. After 12h, colourless crystals were formed. Crystal analysis studies were done by Bruker APEX-II CCD (Figure 1 *vide infra*).

Crystal Structure was deposited at the Cambridge Crystallographic Data Centre. The data have been assigned the following deposition number.

Compound Code: **38** [CCDC number **2070969**]

■ Table 3. Crystal data and structure refinement for compound 38

Compound 9	X-ray crystallography data
Empirical Formula	C ₁₈ H ₁₄ N ₂ O ₂
Formula weight	290.31
Crystal System	Triclinic
Space Group	<i>P</i> ⁱ
T (K)	100
<i>a</i> (Å)	7.2558 (7)
<i>b</i> (Å)	9.8044 (10)
<i>c</i> (Å)	10.5031 (10)
α (°)	99.055 (4)
β (°)	105.174 (4)
γ (°)	103.419 (4)
<i>V</i> (Å ³)	682.24 (12)
<i>D</i> _{cal} (g cm ⁻³)	1.413 Mg m ⁻³
μ (mm ⁻¹)	0.09
<i>Z</i>	2
<i>R</i> [<i>F</i> 2 > 2 σ (<i>F</i> 2)]	0.047
<i>R</i> int	0.065
(sin θ/λ) _{max} (Å ⁻¹)	0.628
R[<i>F</i> 2 > 2 σ (<i>F</i> 2)]	0.047
wR(<i>F</i> ²)	0.131
Crystal size (mm)	0.12 × 0.12 × 0.08
Measured reflections	13705
Independent reflections	2806
Reflections with <i>I</i> > 2 σ (<i>I</i>)	2473
Goodness of fit (S)	1.11
X-ray Diffractometer	Bruker D8 VENTURE Kappa Duo PHOTON II CPAD




Figure S2: Molecular structure (ORTEP diagram) of compound **38** Ellipsoids are shown at 50% probability

■ References:

1. APEX2; SAINT; SADABS In *Bruker AXS Inc*; Bruker Madison, Wisconsin, USA, 2006.
2. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Cryst.*, 2009, 339–341.
3. G. M. Sheldrick, *Acta Cryst.*, 2015, **A71**, 3–8.
4. C. F. Macrae, P. R. Edgington, P. McCabe, E. Pidcock, G. P. Shields, R. Taylor, M. Towler and J. van de Streek, *J. Appl. Cryst.*, 2006, **39**, 453–457.